treatment-resistant depression
Articles tagged with “treatment-resistant depression”
Is Ketamine the Future of Mental Health Treatment?
A local news segment spotlights ketamine therapy's growing role in mental health. Here's what the coverage gets right — and what patients should know.
Psych Deprescribing Debate: What It Means for Ketamine
HHS targets psychiatric overprescribing. Experts say stop what's not working—and replace it with evidence-based alternatives. Here's how ketamine fits in.
Faster TRD Remission: Why Measurement-Based Care Matters
New clinical guidance on TRD emphasizes fast dose adjustments and symptom tracking—here's what it means for patients considering ketamine therapy.
Faster TRD Remission: What Smarter Dosing Means for You
New guidance on treatment-resistant depression stresses faster dose adjustments and symptom tracking. Here's what it means for ketamine therapy patients.
Ketamine Side Effects: What the Data Now Shows
New clinical guidance on NMDA antagonist side effects and discontinuation rates gives ketamine patients a clearer picture of what to expect and when to switch.
Ketamine vs. Esketamine: Side Effects and Who Stops Treatment
New clinical guidance on NMDA antagonist side effects and dropout rates helps patients make smarter choices about ketamine-based depression treatment.
Ketamine for TRD Works Better When Clinics Measure It
New research highlights how symptom tracking and dose optimization help treatment-resistant depression patients reach remission faster with ketamine.
Faster TRD Remission: What Better Protocols Mean for You
New guidance on TRD treatment highlights faster dose adjustment and symptom tracking. Here's what it means for patients considering ketamine.
Getting TRD Patients to Remission Faster in 2026
New analysis in Psychiatric Times shows measurement-based care and rapid dose adjustment get TRD patients to remission faster — here's what that means for ketamine.
How Active Clinical Management Speeds Up TRD Recovery
New analysis shows faster symptom tracking and dose adjustments lead to quicker TRD remission—here's what that means for ketamine therapy.
BPL-003 Shows Lasting Relief for Treatment-Resistant Depression
New phase 2a results for BPL-003 show sustained symptom reduction in treatment-resistant depression. What this means for ketamine patients.
Esketamine's Role in Treatment-Resistant Depression
Clinicians are turning to esketamine for TRD and suicidal depression. Here's what patients need to know about access, cost, and how it compares to IV ketamine.
Why Settling for 'Less Bad' Depression Isn't Enough
Clinicians are pushing for aggressive TRD care aimed at full remission. Here's what that means for patients exploring ketamine treatment options.
BPL-003 Shows Lasting TRD Relief in Phase 2a Results
New phase 2a data on BPL-003 shows sustained symptom reduction in treatment-resistant depression. Here's what it means for ketamine patients.
New Ketamine Nasal Spray Shows Lasting Depression Relief
BPL-003, a novel ketamine nasal spray for treatment-resistant depression, shows sustained symptom reduction in Phase 2a trials. What patients should know.
Contact Ketamine Resource
Send corrections, partnership questions, or advertising inquiries.